Loss of ARID1A Expression as a Favorable Prognostic Factor in Early-Stage Grade 3 Endometrioid Endometrial Carcinoma Patients

Introduction: High-risk patients with grade 3 endometrioid endometrial carcinoma (G3EEC) who require adjuvant therapy have not been clearly identified. Therefore, the current study aimed to investigate the prognostic impact of ARID1A, p53, and mismatch repair (MMR) protein expressions, previously re...

Descripción completa

Detalles Bibliográficos
Autores principales: Kato, Mayumi Kobayashi, Yoshida, Hiroshi, Tanase, Yasuhito, Uno, Masaya, Ishikawa, Mitsuya, Kato, Tomoyasu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Society Journal Archive
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8262237/
https://www.ncbi.nlm.nih.gov/pubmed/34257552
http://dx.doi.org/10.3389/pore.2021.598550

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8262237/
https://www.ncbi.nlm.nih.gov/pubmed/34257552
http://dx.doi.org/10.3389/pore.2021.598550

Ejemplares similares